Goldman Sachs Group Inc

ChrysCapital-backed Intas Pharma weighs $1-bn bid for Biogen's biosimilars biz

Intas Pharmaceuticals Ltd is preparing a bid for Biogen Inc.’s biosimilar business in a transaction that could be valued at ......

• Ranjani Raghavan